Anika Therapeutics Gets FDA Clearance for Injectable Bone Substitute

Anika Therapeutics has received an additional 510(k) clearance from the FDA for its Tactoset injectable bone substitute.

Tactoset is a calcium phosphate-based, biocompatible bone graft substitute that uses Anika’s hyaluronic acid technology.

The newly cleared indication expands the use of Tactoset to include augmentation of hardware and the support of bone fragments during surgical procedures. This means the Bedford, Mass.-based company can now market Tactoset for augmentation of suture-anchor fixation, in addition to treatment of skeletal system defects.